L.a.n.c.e. Chemosensitivitätstestung auf höchstem Niveau · Laborgesellschaft für angewandte Neoplasieforschung und Cytostatika-Evaluation mbH ·

Literatur Zum ATP-TCA liegen zahlreiche wissenschaftliche Studienergebnisse vor. Vor allem die klinischen Studien belegen die hohe prädiktive Aussagefähigkeit des Verfahrens, das sich nicht nur bei der individuellen Therapieplanung, sondern auch in der Entwicklung innovativer Therapieregime bereits hervorragend bewährt hat.

Internationale Literatur
A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
Feasibility of chemosensitivity testing in soft tissue sarcomas.
Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci.
In vitro chemosensitivity to gemcitabine, oxaliplatin and zoledronic acid predicts treatment response in metastatic gastric cancer.
ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials.
Chemosensitivity testing in malignant melanoma.
Chemosensitivity testing in gynecologic oncology–dream or reality?

Trojan J, Kim SZ, Engels K, Kriener S, Mitrou PS, Chow KU.
Anticancer Drugs. 2005 Jan;16(1):87-91.

Division of Gastroenterology, Department of Internal Medicine, Johann Wolfgang Goethe University Medical Center, Frankfurt, Germany.

Individual response of disseminated cancer to chemotherapy is unpredictable. In vitro chemotherapy-induced apoptosis can be measured and might be a method to evaluate in vivo activity of tested drugs. In this report, tumor cells of a patient with signet cell carcinoma of the stomach and diffuse bone marrow infiltration were cultured and tested for in vitro chemosensitivity. The drugs gemcitabine, oxaliplatin and zoledronic acid were found to induce in vitro tumor cell apoptosis synergistically, and subsequently were used as combination chemotherapy regimen. An initially existing disseminated intravascular coagulopathy quickly resolved and after 6 months of treatment on ongoing complete response was induced, thus confirming the results of in vitro chemosensitivity testing.